Sunday 18 October 2026
Export QTTB’s income statement to Excel — free account
Q32 Bio Inc.
QTTB Healthcare Biotechnology
Q32 Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.7 million. In the quarter to June 2026, EPS grew 43.6%, free cash flow grew 71.1% and total debt fell 35.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.52
0.25
−3.22%
Follow QTTB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 72.14% | 157.18% | 125.06% | 55,030.07% |
+8 more TTM periods Free account |
|
| 37.13% | 46.58% | 38.70% | (51.87%) | ||
ROIC |
0.00% | (540.26%) | (672.17%) | 0.00% | |
Return on Tangible Assets |
32.16% | 70.10% | 66.74% | (103.26%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.97) | (1.94) | (2.16) | (3.17) | |
Free Cash Flow |
(19.83) | (27.40) | (26.62) | (38.79) | |
Capital Expenditures |
— | — | 6.93 | — | |
| Other line items | |||||
Cash ROIC |
(9.35%) | (26.04%) | (26.61%) | (92.75%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
(0.59) | (0.82) | (1.12) | 0.92 | |
Depreciation/Fixed assets |
0.50 | 0.59 | 0.58 | 0.57 | |
Capex/Depreciation |
0.00 | 0.00 | 12.13 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.97) | (1.94) | (2.73) | (3.17) | |
Capex per Share |
0.00 | 0.00 | 0.56 | 0.00 | |
Capex to Sales |
— | — | 0.00 | — |
Columns are period end dates